Treatment Outcomes for Men with Clinical Stage II Nonseminomatous Germ Cell Tumours Treated with Primary Retroperitoneal Lymph Node Dissection: A Systematic Review.

Publikation

Treatment Outcomes for Men with Clinical Stage II Nonseminomatous Germ Cell Tumours Treated with Primary Retroperitoneal Lymph Node Dissection: A Systematic Review.

Wissenschaftlicher Artikel/Review - 12.11.2022

Neuenschwander Anne, Lonati Chiara, Antonelli Luca, Papachristofilou Alexandros, Cathomas Richard, Rothermundt Christian, Templeton Arnoud J, Gulamhusein Aziz, Fischer Stefanie, Gillessen Silke, Hermanns Thomas, Lorch Anja, Mattei Agostino, Fankhauser Christian D

Zitation

Neuenschwander A, Lonati C, Antonelli L, Papachristofilou A, Cathomas R, Rothermundt C, Templeton A, Gulamhusein A, Fischer S, Gillessen S, Hermanns T, Lorch A, Mattei A, Fankhauser C. Treatment Outcomes for Men with Clinical Stage II Nonseminomatous Germ Cell Tumours Treated with Primary Retroperitoneal Lymph Node Dissection: A Systematic Review. Eur Urol Focus 2022

Art

Wissenschaftlicher Artikel/Review (Englisch)

Zeitschrift

Eur Urol Focus 2022

Veröffentlichungsdatum

12.11.2022

eISSN (Online)

2405-4569

Kurzbeschreibung/Zielsetzung

Guidelines recommend primary retroperitoneal lymph node dissection (RPLND) as a treatment option for tumour marker-negative stage II nonseminomatous germ cell tumour (NSGCT).